Diagnosis (Laboratory other parameters)
(Die Seite wurde neu angelegt: „'''Presepsin''' {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}} '''Procalcitonin''' {{tp|p=32344321|t=2020. Progn…“)
Zum nächsten Versionsunterschied →
Version vom 22. Juni 2020, 09:50 Uhr
Presepsin
32333860 2020. Presepsin in risk stratification of SARS-CoV-2 patients
Procalcitonin
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
SAA serum amyloid a
32277967 ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19)
suPAR
32354367 2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
CRP
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32281668 2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early
32455147 ä. C reactive protein level may predict the risk of COVID-19 aggravation
IL-6
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32259560 ä. Interleukin-6 as a potential biomarker of COVID-19 progression
32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection
32297995 2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients
NLratio
32283162 ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19
32242828 2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
Troponin
32348472 ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?
Eosinophils
| 32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |
32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)
IL2R on lymphcytes'
32365221 2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19
tumor markers
32347972 2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19
profiling multiple parameters, reviews
32283164 ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China
32324595 2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness
32301746 2020. Routine blood tests as a potential diagnostic tool for COVID-19
32119647 2020. Laboratory abnormalities in patients with COVID-2019 infection
32172227 2020. Laboratory abnormalities in children with novel coronavirus disease 2019
| 32286245 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis |
32181911 ä. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID?19
C7107806 ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury
32452410 2020. Association of viral load with serum biomakers among COVID-19 cases
